Tricyclic antidepressants (TCA) may improve atomoxetine's efficacy

International Journal of Neuropsychopharmacology

Volumn 11, Issue 6, 2008, Pages 877-

  Niederhofer, Helmut ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATOMOXETINE; PAROXETINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ATTENTION DEFICIT DISORDER; CASE REPORT; CHILD; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; LETTER; MALE; PRIORITY JOURNAL;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; PROPYLAMINES;

EID: 50849087088     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708008651     Document Type: Letter

References (2)

1. Paulzen M, Clement HW, Gründer G (2007). Enhancement of atomoxetine serum levels by co-administration of paroxetine. International Journal of Neuropsychopharmacology. Published online: 28 September 2007. doi:10.1017/S1461145707008115.
2. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP (2005). Atomoxetine: a new treatment for attention deficit/hyperactivity disorder (ADHD) in children and adolescents. Encephale 31, 337-348.